Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels of liver enzymes were normal, with only alanine aminotransferase being slightly elevated. Liver biopsy revealed toxic hepatitis of minor grade with periportal fibrosis and intrahepatic cholestasis. Medical treatment of the patient was conservative. Despite the therapy the patient's general condition deteriorated - bilirubin level increased to 56.64 mg/dl, and INR rose to 1.7. Then we decided to administer low doses of hydrocortisone. As a result of the treatment, bilirubin concentration was 14.61 mg/dl after 2 weeks. Finally all hepatic enzymes returned to normal values 5 months after stanozolol was discontinued. This treatment appears to be safe and leads to a more rapid reduction of bilirubin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421162PMC
http://dx.doi.org/10.5114/ceh.2015.51376DOI Listing

Publication Analysis

Top Keywords

intrahepatic cholestasis
8
bilirubin concentration
8
severe intrahepatic
4
cholestasis liver
4
liver failure
4
stanozolol
4
failure stanozolol
4
stanozolol usage
4
usage case
4
case report
4

Similar Publications

: Patients with progressive familial intrahepatic cholestasis (PFIC) experience cholestasis-associated symptoms, including severe pruritus. Odevixibat is an ileal bile acid transporter inhibitor indicated for treatment of PFIC in the European Union and for the treatment of pruritus in PFIC in the United States. The aim of the current study was to characterize the real-world effectiveness and safety of odevixibat in patients with PFIC.

View Article and Find Full Text PDF
Article Synopsis
  • A method was developed to model liver cirrhosis in male Wistar rats by performing a significant liver resection (about 70% volume).
  • After surgery, one group received ademetionine while the control group got saline; both had various tests conducted on them over a 14-day period.
  • Results indicated that the ademetionine group experienced notable liver dysfunction, with laboratory tests showing significant abnormalities, along with observable fibrotic, cirrhotic, and inflammatory liver changes that persisted beyond the testing period.
View Article and Find Full Text PDF

Craniosynostosis as a cause of intracranial hypertension in Alagille syndrome: a case series of 6 consecutive pediatric patients.

Neurosurg Focus

January 2025

1Department of Pediatric Neurosurgery, Hôpital Necker - Enfants Malades, Assistance Publique-Hôpitaux de Paris.

Objective: Craniosynostoses are an underrecognized cause of intracranial hypertension (ICH), especially when associated with congenital syndromes. Alagille syndrome (ALGS) is a multisystem disorder with typical facial features and hepatobiliary, cardiac, vascular, skeletal, and ocular manifestations. The occurrence of craniosynostosis in ALGS is rare and can be associated with chronic ICH, requiring craniofacial surgery to increase the intracranial volume.

View Article and Find Full Text PDF

Background/aim: Two retrospective studies of prospective cohorts showed doubled odds of birth asphyxia among women with low plasma vitamin D levels, and another study reported a four-fold increased risk of stillbirth. It was not known whether this was related to low sun exposure or to insufficient vitamin D per se. We aimed to assess if it was due to vitamin D status.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!